U.S. panel to consider approval of Roche's Actemra in July

06/5/2008 | Reuters

The FDA's Arthritis Advisory Committee is scheduled on July 29 to review Roche Holding's Actemra for approval. The company believes that the drug, which has been approved in Japan, will gain competitive advantage as an alternative to anti-tumor necrosis factor drugs used in rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Stop Loss Sales Executive
Blue Cross Blue Shield of Massachusetts
Boston, MA
Senior Director, Research
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide